ESMO 2018 | Future steps in translational medicine for early to late stage lung cancer
Finding predictive biomarkers is a priority for stage 4 disease management, says Giorgio Scagliotti, MD, PhD, of the University of Torino, Torino, Italy, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. New therapeutic agents are on the horizon; however, Dr Scagliotti suggests to look at these in the context of precision medicine rather than generic treatment. Early detection screening methods for lung cancer are also being looked at, while new adjuvant studies should be supplemented with tumor molecular analysis.
Get great new content delivered to your inboxSign up